Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.42
+0.04002.90%
Post-market: 1.440.0200+1.41%19:47 EDT
Volume:172.13K
Turnover:242.30K
Market Cap:80.33M
PE:-4.96
High:1.45
Open:1.39
Low:1.38
Close:1.38
Loading ...

IceCure Medical files to sell ordinary shares and warrants, no amount given

TIPRANKS
·
16 Oct 2024

Icecure Medical: A Strong Buy on Clinical Success and Upcoming Regulatory Catalysts

TIPRANKS
·
14 Oct 2024

Alignment HealthCare Partners With Intermountain Health in Nevada

Zacks
·
10 Oct 2024

IceCure’s ProSense Excels in Global Cryoablation Studies

TIPRANKS
·
07 Oct 2024

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

PR Newswire
·
07 Oct 2024

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks
·
03 Oct 2024

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks
·
02 Oct 2024

IceCure Medical’s ProSense® Shows Promising Trial Results

TIPRANKS
·
24 Sep 2024

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

PR Newswire
·
24 Sep 2024

IceCure’s ProSense Shows High Success in Tumor Treatment

TIPRANKS
·
16 Sep 2024

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

PR Newswire
·
16 Sep 2024

Icecure Medical Price Target Maintained With a $2.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Sep 2024

IceCure Medical’s ProSense Positioned for Market Success Following FDA Panel Meeting, Analyst Maintains Buy Rating

TIPRANKS
·
13 Sep 2024

BRIEF-IceCure Medical Says FDA Advisory Panel Meeting Date For Marketing Authorization Of ProSense Scheduled For Nov 7

Reuters
·
12 Sep 2024

IceCure’s ProSense® Awaits FDA Panel Review

TIPRANKS
·
12 Sep 2024

Icecure Medical Ltd - FDA Decision Regarding Marketing Authorization of Prosense® Expected by Early 2025

THOMSON REUTERS
·
12 Sep 2024